Molecular structure of Cinobufotalin, CAS Number: 1108-68-5
Cinobufotalin (CAS 1108-68-5)
See product citations (3)
Application:
Cinobufotalin is a specific Na+/K+-ATPase inhibitor
CAS Number:
1108-68-5
Purity:
≥98%
Molecular Weight:
458.6
Molecular Formula:
C26H34O7
Supplemental Information:
This is as a Dangerous Good for transport and may be subject to additional shipping charges.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Product Citations
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Cinobufotalin is a cardioactive steroid of the bufadienolide class that acts as a specific Na+/K+ ATPase inhibitor. Its inhibitory effects has been experimentally determined to be less active than ouabain. Cinobufotalin has also been observed to contain a significant inhibitory effect on hepatitis B virus (HBV) replication. Found to be a component in Chan Su derived from dried toad venom.
Cinobufotalin (CAS 1108-68-5) References
- Efficacy of digoxin specific Fab fragments (Digibind) in the treatment of toad venom poisoning. | Brubacher, JR., et al. 1999. Toxicon. 37: 931-42. PMID: 10340832
- Cardiotonic steroids differentially affect intracellular Na+ and [Na+]i/[K+]i-independent signaling in C7-MDCK cells. | Akimova, OA., et al. 2005. J Biol Chem. 280: 832-9. PMID: 15494417
- Elucidation of the Differences in Cinobufotalin's Pharmacokinetics Between Normal and Diethylnitrosamine-Injured Rats: The Role of P-Glycoprotein. | Zhang, X., et al. 2019. Front Pharmacol. 10: 521. PMID: 31156437
- Cinobufotalin powerfully reversed EBV-miR-BART22-induced cisplatin resistance via stimulating MAP2K4 to antagonize non-muscle myosin heavy chain IIA/glycogen synthase 3β/β-catenin signaling pathway. | Liu, Y., et al. 2019. EBioMedicine. 48: 386-404. PMID: 31594754
- Safety reassessment of cinobufotalin injection: new findings into cardiotoxicity. | Li, M., et al. 2020. Toxicol Res (Camb). 9: 390-398. PMID: 32905219
- Combined Treatment of Cinobufotalin and Gefitinib Exhibits Potent Efficacy against Lung Cancer. | Han, Y., et al. 2021. Evid Based Complement Alternat Med. 2021: 6612365. PMID: 34122599
- Novel SREBP1 inhibitor cinobufotalin suppresses proliferation of hepatocellular carcinoma by targeting lipogenesis. | Meng, H., et al. 2021. Eur J Pharmacol. 906: 174280. PMID: 34174265
- Cinobufotalin inhibits the epithelial-mesenchymal transition of hepatocellular carcinoma cells through down-regulate β-catenin in vitro and in vivo. | Li, W., et al. 2022. Eur J Pharmacol. 922: 174886. PMID: 35292248
- The small molecule chemical compound cinobufotalin attenuates resistance to DDP by inducing ENKUR expression to suppress MYH9-mediated c-Myc deubiquitination in lung adenocarcinoma. | Liu, JH., et al. 2022. Acta Pharmacol Sin. 43: 2687-2695. PMID: 35296779
- ENKUR expression induced by chemically synthesized cinobufotalin suppresses malignant activities of hepatocellular carcinoma by modulating β-catenin/c-Jun/MYH9/USP7/c-Myc axis. | Hou, R., et al. 2022. Int J Biol Sci. 18: 2553-2567. PMID: 35414777
- Phosphoproteomics reveals that cinobufotalin promotes intrahepatic cholangiocarcinoma cell apoptosis by activating the ATM/CHK2/p53 signaling pathway. | Xia, Z., et al. 2022. Front Oncol. 12: 982961. PMID: 36185307
- Cinobufotalin Induces Ferroptosis to Suppress Lung Cancer Cell Growth by lncRNA LINC00597/hsa-miR-367-3p/TFRC Pathway via Resibufogenin. | Huang, J., et al. 2023. Anticancer Agents Med Chem. 23: 717-725. PMID: 36221890
- [Clinical study on cinobufotalin in treating chronic hepatitis B virus carriers]. | Xu, XT. 1993. Zhongguo Zhong Xi Yi Jie He Za Zhi. 13: 473-5, 453-4. PMID: 8111200
Inhibitor of:
ATPase, and Sodium/Potassium-ATPase Protein.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Cinobufotalin, 5 mg | sc-202101 | 5 mg | $162.00 |